Invitrogen™ IL-33R (ST2) Monoclonal Antibody (RMST2-2), APC, eBioscience™, Invitrogen™

Descripción

Description: The RMST2-2 monoclonal antibody reacts with ST2, also known as IL-33 receptor (IL-33R) or interleukin 1 receptor-like 1. ST2 is a member of the IL-1 receptor family. In the membrane-bound form, it consists of three extra-cellular immunoglobulin domains and an intracellular toll-interleukin-1 receptor domain. ST2 forms a dimer with IL-1R accessory protein in a ligand-dependent manner. The IL-33/ST2 interaction induces the production of TH2 cytokines. ST2 also has a soluble isoform lacking transmembrane and intracellular toll-interleukin-1 receptor domains. It is believed that the soluble form functions as a decoy receptor that can block membrane bound IL-33/ST2 interaction. ST2 is expressed by TH2 lymphocytes, mast cells, eosinophils, basophils, innate lymphocytes, smooth muscle cells, and endothelial cells and is involved in host defense, allergy, and inflammation. The IL-33/ST2 interaction has also been shown to be atheroprotective. Applications Reported: This RMST2-2 antibody has been reported for use in flow cytometric analysis. Applications Tested: This RMST2-2 antibody has been tested by flow cytometric analysis of mouse bone marrow-derived mast cells. This can be used at less than or equal to 0.25 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.

IL-33R, also known as ST2, is a receptor for IL-33. It is a member of the IL-1 receptor family of innate receptors. Its extracellular domain consists of 3 Ig-like domains that directly interact with its co-receptor IL-1RAcP, and the ligand alarmin, IL-33. IL-33 ligation results in the association of IL-33R complex with its adaptor proteins MyD88, IRAK1, IRAK4 and TRAF6, and activation of the NF-kB, and MAPK pathways. This, in turn, instigates the release of chemokines and cytokines such as IL-5, IL-6, IL-8, and IL-13. Two most common isoforms of IL-33R that result from alternative splicing are ST2L – the membrane bound form, and ST2S – the soluble form. The membrane bound form can be released from the cell surface by proteolytic cleavage. The soluble forms have been suggested to act as decoys dampening the IL-33 signaling. IL-33R is primarily expressed by mast cells, basophils, and eosinophils. In mouse, IL-33R expression has been shown on ILC2 and Th2 cells. IL-33R signaling has been implicated in the number of immune conditions, including allergies, arthritis, atherosclerosis and sepsis.